drugset / Trial / NCT00134394

Etanercept With Tacrolimus for Psoriasis

NCT00134394

RandomizedParallel-groupDouble-blindTreatment

Summary

The study is designed to evaluate the efficacy of etanercept 50 mg subcutaneously (SQ) weekly plus tacrolimus 0.1% topical ointment twice daily compared to etanercept 50 mg SQ weekly plus placebo ointment twice daily.

Timeline

Start
2005-02
Primary completion
Completion
2007-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Tacrolimus Small molecule 0.1 % Topical
Background Etanercept Protein / enzyme biologic 50 mg Subcutaneous

Indications